Influence of gut microbiome on multiple myeloma: friend or foe?
Authors:
Open Access
- 23 June 2020
- journal article
- editorial
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 8 (1) , e000576
Abstract
Multiple myeloma (MM) is a malignancy of terminally differentiated plasma cells, which typically evolves over time from its precursor, monoclonal gammopathy of undetermined significance. While the underlying mechanisms of this evolution remain elusive, immunomodulatory factors affecting the bone marrow (BM) microenvironment are suspected to play a role. There is an increasing evidence that the gut microbiome exerts an influence on its host’s adaptive and innate immune systems, inflammatory pathways and the BM microenvironment. Dysbiosis, therefore, may impact tumorigenesis in MM. This article gives an overview of potential mechanisms by which the microbiome may influence the pathogenesis of MM, MM patients’ responses to treatment and toxicities experienced by MM patients undergoing autologous transplant. It also discusses the potential role of the mycobiome in MM, a less studied component of the microbiome.Keywords
This publication has 18 references indexed in Scilit:
- Cooperative Evolutionary Strategy between the Bacteriome and MycobiomemBio, 2016
- The human microbiome in hematopoiesis and hematologic disordersBlood, 2015
- Using Corticosteroids to Reshape the Gut MicrobiomeInflammatory Bowel Diseases, 2015
- CD4+T cells in chronic autoantigenic stimulation in MGUS, multiple myeloma and Waldenström's macroglobulinemiaInternational Journal of Cancer, 2015
- Altered Gut Microbiota Composition in Rag1-deficient Mice Contributes to Modulating Homeostasis of Hematopoietic Stem and Progenitor CellsImmune Network, 2015
- Targeting the bone marrow microenvironment in multiple myelomaImmunological Reviews, 2014
- Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma: A Review of the Current Understanding of Epidemiology, Biology, Risk Stratification, and Management of Myeloma Precursor DiseaseClinical Cancer Research, 2013
- A novel role of IL-17–producing lymphocytes in mediating lytic bone disease in multiple myelomaBlood, 2010
- Elevated IL-17 produced by Th17 cells promotes myeloma cell growth and inhibits immune function in multiple myelomaBlood, 2010
- B7+ T Cells in Myeloma: an Acquired Marker of Prior Chronic Antigen PresentationLeukemia & Lymphoma, 2004